首页>
外国专利>
Phosphatidylinositol-3-kinase p110 delta-targeted drugs in the treatment of CNS disorders
Phosphatidylinositol-3-kinase p110 delta-targeted drugs in the treatment of CNS disorders
展开▼
机译:磷脂酰肌醇-3-激酶p110增量靶向药物治疗中枢神经系统疾病
展开▼
页面导航
摘要
著录项
相似文献
摘要
Methods for treating CNS disorders such as schizophrenia, psychosis and cognitive disorders using specific inhibitors of phosphatidylinositol-3-kinase p110 delta (PIK3CD) expression and/or activity are described. Methods of determining risk of CNS disorders and methods of determining treatment response are also described. An integrative systems biology approach to identify a signaling mechanism and genetic network associated with schizophrenia and with schizophrenia-associated risk variation in ErbB4. A risk pathway associated with ErbB4 genetic variation involving increased expression of a PI3K-linked ErbB4 receptor CYT-1 and a specific PI3K enzyme, PIK3CD has been identified.
展开▼